Edwards Lifesciences Beat Expectations

Edwards Lifesciences (EW) reported earnings of $0.67 per share on revenue of $1.53 billion for the second quarter ended June 2025. The consensus earnings estimate was $0.62 per share on revenue of $1.49 billion. The Earnings Whisper number was $0.65 per share. The company beat expectations by 3.08% while revenue grew 10.56% on a year-over-year basis.

The company said it now expects 2025 earnings to be at the high-end of its previous guidance range of $2.40 to $2.50 per share and revenue of $5.93 billion to $6.10 billion. The company's previous guidance was revenue of $5.70 billion to $6.10 billion and the current consensus earnings estimate is $2.46 per share on revenue of $5.91 billion for the year ending December 31, 2025.

Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring.